Our paper of the month for March is a phase 3 multicentre, double-blind, randomised trial investigating whether treatment with exenatide can slow the progression of Parkinson’s disease.
EAN Treasurer, Jana Midelfart-Hoff reviews her "fantastic experience" in office over the last six months, representing the EAN and the Brain Health Mission on various levels
For February we have selected two co-papers of the month, each of which examines the safety and efficacy of a specific drug in the treatment of patients with generalised myasthenia gravis.
EAN Programme Committee Chair, Irena Rektorova, provides an extensive preview of the EAN Congress 2025, looking at programme highlights, new features, and how you can get involved!
Our paper of the month compares drug prescription prior to the clinical onset of sporadic Creutzfeldt-Jakob disease in patients versus matched controls aiming to uncover potential risk or protective factors.
EAN President, Prof. Elena Moro, looks back at some highlights of a successful 10th anniversary year for the EAN, and ahead to some exciting plans for 2025.
Each month the eanNews editorial team reviews the scientific press for recently published papers of outstanding interest to neurologists. Here we present our selection for December 2024.
Our paper of the month highlights the findings of the stage 2 interim analysis from the first cycle of MND SMART, a phase 3, multi-arm, randomised, adaptive platform trial conducted across 20 centres in the UK.
Dr Giacomo Sferruzza, the new EAN Resident & Research Fellow Section (RRFS) Chair, gives an overview of the RRFS Office team, and their aims and priorities for the term ahead.
Our paper of the month for November presents the findings from two large trials comparing the safety and efficacy of evobrutinib with teriflunomide in adults with a diagnosis of relapsing MS.
Each month the eanNews editorial team reviews the scientific press for recently published papers of outstanding interest to neurologists. Here we present our selection for November 2024.